Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans

Phase IB Study to Evaluate the Biological Activity of Indibulin Using Positron-Emission Tomography (PET) Scans

Single arm, open label, Phase IB study of indibulin capsules in subjects with advanced solid tumors; eligible subjects will have a baseline PET scan showing a standardized uptake value (SUV) of ≥5.0 in ≥1 lesion on an 18F-FDG (fluorine-18-labeled deoxyglucose) scale.

Study Overview

• Status: Completed
• Conditions: Advanced Cancer
• Intervention / Treatment: Drug: indibulin

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Santa Monica, California, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Histological or cytological confirmation of advanced cancer, refractory to standard therapies.
2. Received at least one prior therapy and requires additional treatment.
3. ≥18 years of age.
4. ECOG performance score ≤ 2 (see Appendix 3).
5. At least one measurable lesion as defined by RECIST (Response evaluation criteria in solid tumors) guidelines (see Appendix 4). If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology. Measurable lesions must NOT have been in a previously irradiated field or injected with biological agents.
6. PET scan showing a standardized uptake value (SUV) of ≥5.0 in at least 1 lesion on an 18F-FDG (fluorine-18-labeled deoxyglucose) scale.
7. Life expectancy ≥12 weeks.

8. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements, to be conducted <2 weeks prior to Day 1:

   • Creatinine ≤1.5 × upper limit of normal (ULN) or calculated creatinine clearance ≥50 cc/minute
   • Total bilirubin ≤1.5 × ULN
   • Alanine transaminase (ALT) and aspartate transaminase (AST) ≤2.5 × ULN
   • White blood cell count ≥3.0 × 109/L
   • Absolute neutrophil count (ANC) ≥1.5 × 109/L
   • Platelets ≥100 × 109/L
   • Hemoglobin ≥10 g/dL
9. Ability to tolerate repeated blood sampling and adequate vascular access.
10. Serum glucose levels ≤200 mg/dL.
11. Provide written informed consent in compliance with ZIOPHARM policies and the Independent Ethics Committee with jurisdiction over the site.
12. Subjects of childbearing potential must agree to use a barrier method of contraception throughout the study and for 3 months after study drug administration.

Exclusion Criteria:

1. New York Heart Association (NYHA) functional class ≥3 or myocardial infarction within 6 months (see Appendix 5).
2. Uncontrolled diabetes mellitus
3. Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation.
4. Pregnancy and/or lactation.
5. Uncontrolled systemic infection (documented with microbiological studies)
6. Any other anti-cancer or immunological therapy during the study or within 4 weeks of study entry. Mitomycin C or nitrosureas should not be given within 6 weeks of study entry.
7. Radiotherapy during the study or within 3 weeks of study entry.
8. Surgery within 4 weeks of start of study drug excluding tumor biopsy for pharmacodynamic parameters.
9. Investigational drug therapy outside of this trial during or within 4 weeks of study entry.
10. History of an invasive second primary malignancy diagnosed within the previous 3 years, except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer.
11. Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results
12. Any condition that is unstable or could jeopardize the safety of the subject and his/her compliance with the study protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Single Arm	Drug: indibulin; dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.; Other Names: ZIO-301

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
anti-tumor effect on PET Scan	7 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
toxicities	6 months

Collaborators and Investigators

• Sponsor: Alaunos Therapeutics
• Investigators: Study Director: Jonathan Lewis, MD, Alaunos Therapeutics

Publications and helpful links

General Publications

• Kapoor S, Srivastava S, Panda D. Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy. Sci Rep. 2018 Aug 17;8(1):12363. doi: 10.1038/s41598-018-30376-y.

Study record dates

Study Major Dates

• Study Start: October 1, 2007
• Primary Completion (Actual): June 1, 2008
• Study Completion (Actual): March 1, 2009

Study Registration Dates

• First Submitted: December 26, 2007
• First Submitted That Met QC Criteria: December 26, 2007
• First Posted (Estimate): January 11, 2008

Study Record Updates

• Last Update Posted (Estimate): July 19, 2012
• Last Update Submitted That Met QC Criteria: July 18, 2012
• Last Verified: July 1, 2012

More Information

Terms related to this study

• Other Study ID Numbers: IBL1003